OptiNose Inc is planning an initial public offering of shares of its common stock to raise $100m.
Based in the US, Optinose is a nasal delivery technology developer. The company plans to use the proceeds from the offering to advance the development of its XHANCE product and for general corporate purposes.
The US-based biotech company involved in developing RNA-based diagnostic kits plans to use the funds to enhance its research and development.
MediWound Ltd plans for an underwritten public offering of shares. The offering also includes a 30-day option for underwriters to purchase 15% of ordinary shares.
The Israeli biotech company plans to use the funds towards research and development, as well as general corporate purposes.
The UK-based robotic systems developer secured $20.3m in July in a series A funding round led by ABB Technology Ventures, bringing the total funds to $46m. The company plans to use the stocks to advance the development of its Versius surgical robotic system.